Zealand Pharma major shareholder announcement: Royce & Associates, LLC, U.S.

Company announcement - No.2/ 2018
Zealand Pharma major shareholder announcement: Royce & Associates, LLC, U.S.

Copenhagen, January 15, 2018 - Zealand Pharma announces that it has received information from Royce & Associates, LLC, U.S., that they have decreased their investment in Zealand Pharma to below 5% of Zealand outstanding shares. Their holding following the decrease amounts to 4.99% or 1,534,556 shares.

For further information, please contact:

Mats Blom, Executive Vice President and Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) (Zealand) is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim as well as a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.

02-18_0115 Major Shareholder announcement


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Zealand Pharma via Globenewswire

\Hugin